Kala Pharmaceuticals Inc (KALA) Expected to Announce Earnings of -$0.37 Per Share

Wall Street brokerages expect that Kala Pharmaceuticals Inc (NASDAQ:KALA) will post earnings per share (EPS) of ($0.37) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Kala Pharmaceuticals’ earnings, with estimates ranging from ($0.43) to ($0.27). The business is expected to issue its next quarterly earnings results on Tuesday, February 6th.

According to Zacks, analysts expect that Kala Pharmaceuticals will report full year earnings of ($2.22) per share for the current fiscal year, with EPS estimates ranging from ($2.72) to ($1.95). For the next year, analysts anticipate that the business will report earnings of ($1.80) per share, with EPS estimates ranging from ($2.10) to ($1.32). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Kala Pharmaceuticals.

Kala Pharmaceuticals (NASDAQ:KALA) last announced its quarterly earnings results on Tuesday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.14).

Several brokerages have recently weighed in on KALA. Wells Fargo & Co reiterated a “buy” rating on shares of Kala Pharmaceuticals in a research report on Friday. BidaskClub upgraded Kala Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, December 29th. Wedbush reiterated an “outperform” rating and issued a $46.00 price target on shares of Kala Pharmaceuticals in a research report on Friday, December 22nd. JPMorgan Chase & Co. set a $35.00 price target on Kala Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, November 19th. Finally, Zacks Investment Research cut Kala Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $36.80.

Kala Pharmaceuticals (NASDAQ:KALA) opened at $13.61 on Tuesday. Kala Pharmaceuticals has a 52-week low of $11.81 and a 52-week high of $26.75. The company has a current ratio of 11.00, a quick ratio of 11.00 and a debt-to-equity ratio of 0.14.

A number of large investors have recently bought and sold shares of the stock. Orbimed Advisors LLC bought a new stake in Kala Pharmaceuticals during the third quarter valued at $54,251,000. Caxton Corp bought a new stake in Kala Pharmaceuticals during the third quarter valued at $12,430,000. Victory Capital Management Inc. bought a new stake in Kala Pharmaceuticals during the third quarter valued at $12,414,000. OxFORD Asset Management LLP bought a new stake in Kala Pharmaceuticals during the third quarter valued at $4,374,000. Finally, JPMorgan Chase & Co. bought a new stake in Kala Pharmaceuticals during the third quarter valued at $4,037,000. 62.96% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Kala Pharmaceuticals Inc (KALA) Expected to Announce Earnings of -$0.37 Per Share” was first reported by BBNS and is the sole property of of BBNS. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/kala-pharmaceuticals-inc-kala-expected-to-announce-earnings-of-0-37-per-share/1820037.html.

About Kala Pharmaceuticals

Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.

Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.